Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David G Standaert

Showing results (61-70 of 188) with videos related to

Pageof 19
Sort By:
NPJ Parkinson'S Disease|February 2, 2018
Systematic evaluation of levodopa-carbidopa intestinal gel patient-responder characteristicsDavid G Standaert, James T Boyd, Per Odin, et al.
Progress in Brain Research|April 6, 2020
Innate and adaptive immune responses in Parkinson's diseaseAubrey M Schonhoff, Gregory P Williams, Zachary D Wallen, et al.
Medrxiv : the Preprint Server for Health Sciences|June 9, 2023
Population fraction of Parkinson's disease attributable to preventable risk factorsHaydeh Payami, Gwendolyn Cohen, Charles F Murchison, et al.
Journal of Neurochemistry|June 7, 2007
Dopamine release is impaired in a mouse model of DYT1 dystoniaAygul Balcioglu, Mee-Ohk Kim, Nutan Sharma, et al.
Experimental Neurology|June 8, 2017
Strength of cholinergic tone dictates the polarity of dopamine D2 receptor modulation of striatal cholinergic interneuron excitability in DYT1 dystoniaMariangela Scarduzio, Chelsea N Zimmerman, Karen L Jaunarajs, et al.
Parkinsonism & Related Disorders|September 20, 2011
Unilateral subthalamic nucleus deep brain stimulation improves sleep quality in Parkinson's diseaseAmy W Amara, David G Standaert, Stephanie Guthrie, et al.
Nature Reviews. Neuroscience|February 21, 2008
The pathophysiological basis of dystoniasXandra O Breakefield, Anne J Blood, Yuqing Li, et al.
NPJ Parkinson'S Disease|December 5, 2023
Population fraction of Parkinson's disease attributable to preventable risk factorsHaydeh Payami, Gwendolyn Cohen, Charles F Murchison, et al.
Scientific Reports|February 1, 2025
Alpha synuclein overexpression can drive microbiome dysbiosis in miceTimothy R Sampson, Zachary D Wallen, Woong-Jai Won, et al.
Journal of Neuroinflammation|September 1, 2018
Targeting of the class II transactivator attenuates inflammation and neurodegeneration in an alpha-synuclein model of Parkinson's diseaseGregory P Williams, Aubrey M Schonhoff, Asta Jurkuvenaite, et al.
Pageof 19

Showing results (61-70 of 188) with videos related to

Sort By:
Pageof 19
NPJ Parkinson'S Disease|February 2, 2018
Systematic evaluation of levodopa-carbidopa intestinal gel patient-responder characteristicsDavid G Standaert, James T Boyd, Per Odin, et al.
Progress in Brain Research|April 6, 2020
Innate and adaptive immune responses in Parkinson's diseaseAubrey M Schonhoff, Gregory P Williams, Zachary D Wallen, et al.
Medrxiv : the Preprint Server for Health Sciences|June 9, 2023
Population fraction of Parkinson's disease attributable to preventable risk factorsHaydeh Payami, Gwendolyn Cohen, Charles F Murchison, et al.
Journal of Neurochemistry|June 7, 2007
Dopamine release is impaired in a mouse model of DYT1 dystoniaAygul Balcioglu, Mee-Ohk Kim, Nutan Sharma, et al.
Experimental Neurology|June 8, 2017
Strength of cholinergic tone dictates the polarity of dopamine D2 receptor modulation of striatal cholinergic interneuron excitability in DYT1 dystoniaMariangela Scarduzio, Chelsea N Zimmerman, Karen L Jaunarajs, et al.
Parkinsonism & Related Disorders|September 20, 2011
Unilateral subthalamic nucleus deep brain stimulation improves sleep quality in Parkinson's diseaseAmy W Amara, David G Standaert, Stephanie Guthrie, et al.
Nature Reviews. Neuroscience|February 21, 2008
The pathophysiological basis of dystoniasXandra O Breakefield, Anne J Blood, Yuqing Li, et al.
NPJ Parkinson'S Disease|December 5, 2023
Population fraction of Parkinson's disease attributable to preventable risk factorsHaydeh Payami, Gwendolyn Cohen, Charles F Murchison, et al.
Scientific Reports|February 1, 2025
Alpha synuclein overexpression can drive microbiome dysbiosis in miceTimothy R Sampson, Zachary D Wallen, Woong-Jai Won, et al.
Journal of Neuroinflammation|September 1, 2018
Targeting of the class II transactivator attenuates inflammation and neurodegeneration in an alpha-synuclein model of Parkinson's diseaseGregory P Williams, Aubrey M Schonhoff, Asta Jurkuvenaite, et al.
Pageof 19